💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Antihemophilic Factor, Pegylated (Mw 20000) Human Sequence Recombinant

CHEMBL4594584 Phase 4 अनुमोदित Unknown
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
508.6 g/mol
LogP
-3.6
Phase
4

A recombinant form of clotting Factor VIII that has been chemically modified with polyethylene glycol to extend its time in circulation, reducing the frequency of injections needed. It is used to prevent and treat bleeding episodes in people with hemophilia A.

आणविक भार

508.6000 g/mol

LogP

-3.60

TPSA

197.00 Ų

लिपिंस्की RO5

अनुत्तीर्ण

क्रिया का तंत्र

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COCCNC(=O)OCC(COC(=O)NCCOC)OCCCC(=O)NCCCC[C@@H](C(=O)O)N

                

                

                
                

                    
InChI

                    
InChI=1S/C21H40N4O10/c1-31-12-9-24-20(29)34-14-16(15-35-21(30)25-10-13-32-2)33-11-5-7-18(26)23-8-4-3-6-17(22)19(27)28/h16-17H,3-15,22H2,1-2H3,(H,23,26)(H,24,29)(H,25,30)(H,27,28)/t17-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H40N4O10

                    

                    
                    

                        
HBD / HBA

                        
5 / 11

                    

                    
                    

                        
घूर्णनीय बंधन

                        
23

                    

                    
                    
                    

                        
भारी परमाणु

                        
35

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
A recombinant form of clotting Factor VIII that has been chemically modified with polyethylene glycol to extend its time in circulation, reducing the frequency of injections needed. It is used to prevent and treat bleeding episodes in people with hemophilia A.

                        

                    

                    

                    

                    
                    

                        
                        

                            
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Antihemophilic Factor, Pegylated (Mw 20000) Human Sequence Recombinant is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4594584.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 86278357.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.